Fig. 2
CAF cross-presentation of processed antigen protects tumour cells from T cell killing. a Quantification of MHC I SIINFEKL detected in FRCs, CAFs and normal fibroblasts following OVA pulse (white bars), and when pulsed in tumour conditioned media (grey bars). b MHC I SIINFEKL detection in the presence of ammonium chloride (grey bars), chloroquine (black bars) and vehicle control (white bars). c MHC I SIINFEKL detected on CAFs after co culture with B16.OVA tumour cells, or CAFs pulsed with soluble OVA. d T cell killing of control parental (B16.F10) and antigen bearing (B16.OVA) target tumour cells in the absence of fibroblasts. e, f B16 viability when introduced to OT-I T cells previously conditioned in the presence/absence of normal fibroblasts (e), CAFs (f) and presence/absence of antigen as indicated on graphs. g Lung tumour cell viability when introduced to OT-I T cells previously conditioned in the presence/absence of normal fibroblasts (yellow bars), CAFs (red bars) and presence/absence of antigen as indicated on graphs. Data shown as mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, one-way ANOVA with Tukey post hoc analysis. NS, not significant. Assays performed in triplicate (a, c, g) or duplicate (b) from two experiments or (d-f) three experiments. Comparisons indicated by horizontal lines
